GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » Shiller PE Ratio

Brainstorm Cell Therapeutics (STU:GHDN) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Brainstorm Cell Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Brainstorm Cell Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Shiller PE Ratio Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Brainstorm Cell Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Shiller PE Ratio falls into.



Brainstorm Cell Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Brainstorm Cell Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Brainstorm Cell Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Brainstorm Cell Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.118 100.560 -0.155
201409 -0.124 100.428 -0.163
201412 -0.146 99.070 -0.194
201503 -0.111 99.621 -0.147
201506 -0.107 100.684 -0.140
201509 -0.125 100.392 -0.164
201512 -0.064 99.792 -0.085
201603 -0.090 100.470 -0.118
201606 -0.045 101.688 -0.058
201609 -0.080 101.861 -0.103
201612 -0.038 101.863 -0.049
201703 -0.093 102.862 -0.119
201706 -0.053 103.349 -0.068
201709 -0.109 104.136 -0.138
201712 0.017 104.011 0.022
201803 -0.097 105.290 -0.121
201806 -0.137 106.317 -0.170
201809 -0.129 106.507 -0.160
201812 -0.237 105.998 -0.295
201903 -0.212 107.251 -0.260
201906 -0.204 108.070 -0.249
201909 -0.227 108.329 -0.276
201912 -0.306 108.420 -0.372
202003 -0.290 108.902 -0.351
202006 -0.222 108.767 -0.269
202009 -0.119 109.815 -0.143
202012 -0.304 109.897 -0.365
202103 -0.160 111.754 -0.189
202106 -0.141 114.631 -0.162
202109 -0.128 115.734 -0.146
202112 -0.150 117.630 -0.168
202203 -0.136 121.301 -0.148
202206 -0.180 125.017 -0.190
202209 -0.192 125.227 -0.202
202212 -0.123 125.222 -0.129
202303 -0.131 127.348 -0.136
202306 -0.120 128.729 -0.123
202309 -0.028 129.860 -0.028
202312 -0.101 129.419 -0.103
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Brainstorm Cell Therapeutics  (STU:GHDN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Brainstorm Cell Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (STU:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (STU:GHDN) Headlines

No Headlines